Tcfg Wealth Management LLC Sells 41 Shares of Stryker Corporation $SYK

Tcfg Wealth Management LLC trimmed its position in Stryker Corporation (NYSE:SYK) by 3.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,062 shares of the medical technology company’s stock after selling 41 shares during the quarter. Tcfg Wealth Management LLC’s holdings in Stryker were worth $420,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares in the last quarter. Vest Financial LLC acquired a new position in Stryker in the first quarter worth about $203,000. Wedmont Private Capital lifted its stake in Stryker by 5.6% during the first quarter. Wedmont Private Capital now owns 3,876 shares of the medical technology company’s stock worth $1,358,000 after purchasing an additional 207 shares during the period. Miracle Mile Advisors LLC lifted its stake in Stryker by 13.0% during the first quarter. Miracle Mile Advisors LLC now owns 7,569 shares of the medical technology company’s stock worth $2,818,000 after purchasing an additional 870 shares during the period. Finally, Park Avenue Securities LLC boosted its holdings in Stryker by 9.3% during the first quarter. Park Avenue Securities LLC now owns 11,597 shares of the medical technology company’s stock valued at $4,317,000 after purchasing an additional 984 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $365.99 on Tuesday. The business’s fifty day moving average is $382.13 and its two-hundred day moving average is $378.92. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $139.92 billion, a P/E ratio of 48.48, a P/E/G ratio of 2.67 and a beta of 0.94. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the subject of a number of recent research reports. Evercore ISI increased their target price on Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Rothschild Redb upgraded Stryker to a “hold” rating in a research report on Thursday, September 18th. BTIG Research reiterated a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Rothschild & Co Redburn initiated coverage on shares of Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price on the stock. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.